Diagnos Seeks Saudi FDA Approval for AI-Driven CARA System

Diagnos ( (TSE:ADK) ) has shared an update.

Diagnos Inc. has announced its filing for Saudi FDA authorization of its CARA SYSTEM, an AI-assisted medical device designed to assist healthcare professionals in detecting diabetic retinopathy, age-related macular degeneration, and hypertensive retinopathy. This strategic move, in collaboration with Kanhoor Medical, aims to enhance diagnostic accuracy and streamline workflows, marking a significant growth phase for Diagnos in the Saudi Arabian market, where diabetes prevalence is notably high.

More about Diagnos

DIAGNOS is a publicly traded Canadian corporation specializing in the early detection of critical health issues using its FLAIRE Artificial Intelligence platform. The company focuses on developing applications like CARA (Computer Assisted Retina Analysis) to enhance diagnostic accuracy and improve patient outcomes globally.

YTD Price Performance: 3.33%

Average Trading Volume: 221,021

Technical Sentiment Consensus Rating: Buy

Current Market Cap: C$31.34M

Find detailed analytics on ADK stock on TipRanks’ Stock Analysis page.